Hosted on MSN26d
How to Tell If You May Have Scalp Psoriasis vs. Dandruff
Psoriasis and dandruff can both trigger itching and flaky scalp skin. Psoriasis is a chronic autoimmune disorder that can cause thick patches of skin known as plaques on the scalp to become dry ...
Dermatology Advisor5h
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Healthline29d
Overview of Generalized Pustular Psoriasis
Generalized pustular psoriasis is a very rare and extreme form of psoriasis. It’s characterized by reoccurring flare-ups that cause pus-filled bumps and red or discolored skin over a large part ...
Medscape28d
Topical Psoriasis Therapies: Tapinarof, Roflumilast, and Newer Fixed Combination Topicals Show Robust Efficacy
according to the analysis of patients with plaque psoriasis. “We typically don’t think about putting cream on the scalp,” she added, but additional research looking at this PAD-formulated ...
Medscape8d
Significant Improvement in Psoriasis Observed With Novel Oral Drug Icotrokinra, in Phase 3 Trial
Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...
Healio13d
Positive results showcase icotrokinra’s ‘unique’ mechanism of action in plaque psoriasis
Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...
The American Journal of Managed Care15d
Deucravacitinib Improves Quality of Life in Patients With Scalp Psoriasis
The first poster was based on findings from the PSORIATYK SCALP (NCT05478499 ... the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Medindia18d
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...
Healio16d
Oral TYK2 inhibitor has ‘outstanding efficiency’ in plaque psoriasis
Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with placebo at week 12. The safety profile of ICP-488 was similar to placebo. ORLANDO — A once ...
manilatimes18d
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1 ... for FDA approval based on the PDUFA for the treatment of scalp and body psoriasis, the ...
Morningstar18d
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis ... based on the PDUFA for the treatment of scalp and body psoriasis, the potential for clinical results for ZORYVE ...